Monopar Therapeutics (MNPR N/A) has faced two volatility halts in its first day of trading. Shares are currently exchanging hands at $26.46, up 231% from its $8 IPO price.
Lead candidate is Fast Track-tagged Validive (clonidine mucobuccal tablet) for the treatment of oral mucositis in oropharyngeal cancer patients undergoing chemo.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.